Skip to main content

AS/Spondyloarthritis

      RT @MeralElRamahiMD: #Eular2021 "Just because they do not have nonradiographic-AxSpa, it does not mean that the disease
      #Eular2021 "Just because they do not have nonradiographic-AxSpa, it does not mean that the disease burden is less (compared to radiographic-AxSpa)!" Dr. Atul Deodhar @RheumNow
      RT @Stiddyo: Crosssectional multicentre study clusters phenotypes of #spondyloarthritis differentiating two types: axial
      3 years 6 months ago
      Crosssectional multicentre study clusters phenotypes of #spondyloarthritis differentiating two types: axial and peripheral, Fitted well to either diagnoses of ax-SpA or #PsA. Still overlap of features like arthritis, dactylitis and enthesitis exists. #OP0047 #EULAR2021 @RheumNow https://t.co/sru9bT4mla
      RT @MeralElRamahiMD: #Eular2021: Is AS & nr-AxSpA the same disease? The current consensus is that they are the two e
      #Eular2021: Is AS & nr-AxSpA the same disease? The current consensus is that they are the two ends of the spectrum -- same disease! @RheumNow https://t.co/r0fTtp3Uip
      RT @MeralElRamahiMD: #EULAR2021 M:F ratio in nr-AxSpa is 1:1. The baseline features between r-AxSpa and nr-AxSpA is simi
      #EULAR2021 M:F ratio in nr-AxSpa is 1:1. The baseline features between r-AxSpa and nr-AxSpA is similar with equal burden of disease. @RheumNow https://t.co/tm9Y6OB5TY
      RT @doctorRBC: Comparison of disease activity and PROs in AxSpA vs. AxPsA
      ⭐️AxSpA ⬆️ uveitis and IBD
      ⭐️AxPsA
      3 years 6 months ago
      Comparison of disease activity and PROs in AxSpA vs. AxPsA ⭐️AxSpA ⬆️ uveitis and IBD ⭐️AxPsA ⬆️enthesitis and dactylitis ⭐️AxSpA pts ⬆️pain, spinal pain PROs ⭐️Fatigue and work impairment did not differ in AxSpA vs AxPsA Abs#OP0049 #EULAR2021 @RheumNow https://t.co/wGD6IA5ahb
      RT @doctorRBC: Secukinumab effective in AS patients, irrespective of gender
      AQUILA 52 week study
      ⭐️improvement in BA
      3 years 6 months ago
      Secukinumab effective in AS patients, irrespective of gender AQUILA 52 week study ⭐️improvement in BASDAI, PGA, severity of depressive mood in both men and women ⭐️women had overall higher disease burden in global functioning and depressive mood POS0899 #EULAR2021 @RheumNow
      RT @doctorRBC: C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA
      ⭐️82% ⬇️ in uveitis flare ev
      3 years 6 months ago
      C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA ⭐️82% ⬇️ in uveitis flare event ⭐️reduction in axSpA disease activity ⭐️no new safety signals POS0897 #EULAR2021 @RheumNow https://t.co/182iHfkSTY
      RT @uptoTate: Quick update from #EULAR2021! Patient reported outcomes are important but how can we use them clinically i
      3 years 6 months ago
      Quick update from #EULAR2021! Patient reported outcomes are important but how can we use them clinically in a meaningful way. Some key SpA/PsA findings from the experts at ASRI and the CorEvitas registry @rheumnow https://t.co/irxQs7Yzrx
      RT @uptoTate: In DESIR AxSpA cohort: only 25% of patients achieved remission at 5 year follow up!!! Lower SES and ^ weig
      3 years 6 months ago
      In DESIR AxSpA cohort: only 25% of patients achieved remission at 5 year follow up!!! Lower SES and ^ weight were negative factors in remission. Abstract #OP0052 #EULAR2021 @RheumNow https://t.co/X4wN1wIGfX https://t.co/DKBIXmEmki
      RT @uptoTate: Female AxSpA pts report worse PROs but have better spinal mobility vs male AxSpA pts. Dz activity pattern
      3 years 6 months ago
      Female AxSpA pts report worse PROs but have better spinal mobility vs male AxSpA pts. Dz activity pattern similar in 4/6 BASDAI components regardless of gender. Females reports ^ fatigue, males report ^ spinal pain. Abstract# OP0051 #EULAR2021 @RheumNow https://t.co/U8T8JEWwCp https://t.co/yNP6PuA8PD
      ×